Kestra Medical CEO sells 15,000 shares on Oct. 20

The president and chief executive officer reported the sales under a Rule 10b5-1 trading plan adopted on July 21, 2026.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) President and Chief Executive Officer Brian Daniel Webster reported two direct sales totaling 15,000 Common Shares on October 20, 2026: 13,316 shares at a weighted average price of $29.5172 and 1,684 shares at $29.8920. Both sales were made under a Rule 10b5-1 trading plan adopted on July 21, 2026.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 2 txns

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($443K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F2	13,316	$29.5172	$393K
Sale	Common Shares F1, F3	1,684	$29.892	$50K

Holdings After Transaction: Common Shares — 445,215 shares (Direct)

Footnotes (3)

1. F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $28.8568 to $29.8475. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $29.8600 to $29.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Common Shares sold: 15,000 shares Common Shares sold: 13,316 shares Weighted average price: $29.5172 per share +4 more

7 metrics

Common Shares sold 15,000 shares Two direct sales on October 20, 2026

Common Shares sold 13,316 shares Sale on October 20, 2026

Weighted average price $29.5172 per share For the sale of 13,316 shares on October 20, 2026

Reported sale price range $28.8568 to $29.8475 per share Sale of 13,316 shares

Common Shares sold 1,684 shares Sale on October 20, 2026

Weighted average price $29.8920 per share For the sale of 1,684 shares on October 20, 2026

Reported sale price range $29.8600 to $29.9200 per share Sale of 1,684 shares

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction technical

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KMTS shares did the CEO sell and at what prices?

Brian Daniel Webster sold 13,316 Common Shares at a weighted average price of $29.5172, with reported sale prices ranging from $28.8568 to $29.8475, and 1,684 Common Shares at a weighted average price of $29.8920, ranging from $29.8600 to $29.9200, on October 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 04:24 PM EDT Accepted by SEC EDGAR 10/22/2026 - 04:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/20/2026	10/20/2026	S(1)		13,316	D	$29.5172(2)	446,899	D
Common Shares	10/20/2026	10/20/2026	S(1)		1,684	D	$29.892(3)	445,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $28.8568 to $29.8475. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $29.8600 to $29.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)